The DOI matches its Crossref record.
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
Abstract
AmBisome is a lyophilizcd preparation of lipaomal amphotericin B. The acute intravenous toxicity of AmBisome was evaluated in mice and rats; and the LD50s were found to be > 175 and 50 mg/kg, respectively. The corresponding LD50 for conventional amphotericin B were approximately 2·3 and 1·6 mg/kg for mice and rats, respectively. The multiple dose toxicity test confirmed that AmBisome was well tolerated by both spocies. There were no deaths observed among mia receiving 25 or 50 mg/kg AmBisome for 14 days, and only two deaths among mice receiving 75 mg/kg AmBisome. One rat died in the group receiving 25 mg/kg AmBisome for 30 days. However, five of ten and nine of ten rats died in the groups treated with 50 and 75 mg/kg AmBisome, respectively. Hepatotoxicity was evident by elevation in serum liver enzyme levels for thesc groups. Initial pharmacokinetic evaluations demonstrated that peak plasma conentrations of 87 and 118 mg/kg, respectively, were attained in mice and rats after injection with 5 mg/kg AmBisome. Terminal plasma half-lives of 3·36 and 7·56 h were calculated for mice and rats, respectively.Tissue accumulations of amphotericin B resulting from multiple dose intravenous administration of either conventional amphotericin B or ArnBisome were determined. At equivalent doses of 1 mg/kg, AmBisome treatment resulted in higher liver and spleen uptake of drug, but lower kidney and lung uptake than amphotericin B.At 5 mg/kg, AmBisome treatment resulted in conantrations of drug in the kidney and lungs that were comparable to corresponding tissue levels obsevered in the group treated with 1 mg/kg conventional amphoterian B. However, liver and spleen conantrations were more than ten-fold greater relative to the group treated with 1 mg/kg conventional drug. The 5 mg/kg AmBisome treatment also resulted in a low, but measurable accumulation of amphotericin B in brain tissue. The results show that the AmBisome formulation has greatly reduced the toxicity of amphotericin B, and high plasma concentrations and tissue accumulations of drug can be achieved with non-toxic doses of AmBisome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Walsh, T. J., Goodman, J. L., Pappas, P., Bekersky, I., Buell, D. N., Roden, M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Metadata
- Authors
- Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., & Adler-Moore, J. P.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-01-01
- Volume
- 28
- Issue
- suppl B
- Pages
- 49-61
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2012504003
- Cited by
- 203
- References
- 0
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. https://app.cochat.ai/papers/10.1093/jac/28.suppl_b.49
- The paper
- Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., & Adler-Moore, J. P. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/28.suppl_b.49
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.